Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: From investigational trials to clinical experience

Journal of Rheumatology

Volumn 27, Issue SUPPL. 60, 2000, Pages 17-24

  Bensen, W G ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Celecoxib; Cyclooxygenase; Inflammation; Osteoarthritis; Pain; Rheumatoid arthritis

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME SPECIFICITY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; OSTEOARTHRITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; DRUG ANTAGONISM; DRUG EFFECT; HIP OSTEOARTHRITIS; JOINT; KNEE OSTEOARTHRITIS; PAIN ASSESSMENT; REVIEW; TREATMENT OUTCOME;

ANALGESICS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS, PHASE III; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; HUMANS; ISOENZYMES; JOINTS; MEMBRANE PROTEINS; NAPROXEN; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0034304296     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Pharmacological and biochemical demonstration of the role of cyclooxygenase (COX)-2 in inflammation and pain
2. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
3. Nonsteroidal antiinflammatory drugs and their effects: The importance of COX 'selectivity'
4. Overview: Mechanisms of action of anti-inflammatory drugs
5. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib)
6. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis
7. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase
8. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
9. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
10. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
11. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
12. The optimal management of early rheumatoid arthritis
13. Nonsteroidal antiinflammatory drugs: Differences and similarities
14. Renal complications associated with use of nonsteroidal anti-inflammatory drugs
15. Celecoxib, a specific COX-2 inhibitor, lacks significant drug-drug interactions with methotrexate or warfarin [abstract]
16. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects
17. Critical appraisal of continuing medical education in the rheumatic diseases for primary care physicians